Literature DB >> 17061040

MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.

Tone F Bathen1, Line R Jensen, Beathe Sitter, Hans E Fjösne, Jostein Halgunset, David E Axelson, Ingrid S Gribbestad, Steinar Lundgren.   

Abstract

The purpose of the study was to evaluate the use of metabolic phenotype, described by high-resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS), as a tool for prediction of histological grade, hormone status, and axillary lymphatic spread in breast cancer patients. Biopsies from breast cancer (n = 91) and adjacent non-involved tissue (n = 48) were excised from patients (n = 77) during surgery. HR MAS MR spectra of intact samples were acquired. Multivariate models relating spectral data to histological grade, lymphatic spread, and hormone status were designed. The multivariate methods applied were variable reduction by principal component analysis (PCA) or partial least-squares regression-uninformative variable elimination (PLS-UVE), and modelling by PLS, probabilistic neural network (PNN), or cascade correlation neural network. In the end, model verification by prediction of blind samples (n = 12) was performed. Validation of PNN training resulted in sensitivity and specificity ranging from 83 to 100% for all predictions. Verification of models by blind sample testing showed that hormone status was well predicted by both PNN and PLS (11 of 12 correct), lymphatic spread was best predicted by PLS (8 of 12), whereas PLS-UVE PNN was the best approach for predicting grade (9 of 12 correct). MR-determined metabolic phenotype may have a future role as a supplement for clinical decision-making-concerning adjuvant treatment and the adaptation to more individualised treatment protocols.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17061040     DOI: 10.1007/s10549-006-9400-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  48 in total

Review 1.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 2.  Metabolomic profiling of hormone-dependent cancers: a bird's eye view.

Authors:  Stacy M Lloyd; James Arnold; Arun Sreekumar
Journal:  Trends Endocrinol Metab       Date:  2015-08-01       Impact factor: 12.015

Review 3.  Metabolomic signature of brain cancer.

Authors:  Renu Pandey; Laura Caflisch; Alessia Lodi; Andrew J Brenner; Stefano Tiziani
Journal:  Mol Carcinog       Date:  2017-07-17       Impact factor: 4.784

4.  Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.

Authors:  J P Wijnen; L Jiang; T R Greenwood; M Cheng; M Döpkens; M D Cao; Z M Bhujwalla; B Krishnamachary; D W J Klomp; K Glunde
Journal:  NMR Biomed       Date:  2014-04-24       Impact factor: 4.044

5.  Clinical applications of breast cancer metabolomics using high-resolution magic angle spinning proton magnetic resonance spectroscopy (HRMAS 1H MRS): systematic scoping review.

Authors:  Almir G V Bitencourt; Johanna Goldberg; Katja Pinker; Sunitha B Thakur
Journal:  Metabolomics       Date:  2019-11-06       Impact factor: 4.290

Review 6.  Applications of high-resolution magic angle spinning MRS in biomedical studies II-Human diseases.

Authors:  Christopher Dietz; Felix Ehret; Francesco Palmas; Lindsey A Vandergrift; Yanni Jiang; Vanessa Schmitt; Vera Dufner; Piet Habbel; Johannes Nowak; Leo L Cheng
Journal:  NMR Biomed       Date:  2017-09-15       Impact factor: 4.044

Review 7.  Biochemical characterization of breast tumors by in vivo and in vitro magnetic resonance spectroscopy (MRS).

Authors:  Uma Sharma; Naranamangalam R Jagannathan
Journal:  Biophys Rev       Date:  2009-01-17

Review 8.  Clinical applications of metabolomics in oncology: a review.

Authors:  Jennifer L Spratlin; Natalie J Serkova; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 9.  Metabolomics-based methods for early disease diagnostics.

Authors:  G A Nagana Gowda; Shucha Zhang; Haiwei Gu; Vincent Asiago; Narasimhamurthy Shanaiah; Daniel Raftery
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

Review 10.  Genomic and proteomic biomarkers for cancer: a multitude of opportunities.

Authors:  Michael A Tainsky
Journal:  Biochim Biophys Acta       Date:  2009-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.